Chapter 9 The Value of Mammalian Models for Duchenne Muscular Dystrophy in Developing Therapeutic Strategies

Current Topics in Developmental Biology

Volumn 84, Issue , 2008, Pages 431-453

  Banks, Glen B ^a   Chamberlain, Jeffrey S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; UTROPHIN;

ANIMAL; DISEASE MODEL; DOG; DUCHENNE MUSCULAR DYSTROPHY; EVALUATION; GENETICS; HUMAN; INJURY; MAMMAL; MOUSE; MUSCLE CONTRACTION; PATHOLOGY; PHYSIOLOGY; REGENERATION; REVIEW; SKELETAL MUSCLE; THERAPY; TRANSGENIC ANIMAL; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; DOGS; DYSTROPHIN; HUMANS; MAMMALS; MICE; MICE, INBRED MDX; MUSCLE CONTRACTION; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; REGENERATION; THERAPEUTICS; UTROPHIN;

EID: 58749101371     PISSN: 00702153     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0070-2153(08)00609-1     Document Type: Review

References (163)

1. Abmayr S., and Chamberlain J.S. The structure and function of dystrophin. In: Winder S. (Ed). The Molecular Mechanisms of Muscular Dystrophy (2004), Landes Bioscience, Georgetown
2. Alderton J.M., and Steinhardt R.A. How calcium influx through calcium leak channels is responsible for the elevated levels of calcium-dependent proteolysis in dystrophic myotubes. Trends Cardiovasc. Med. 10 (2000) 268-272
3. Alter J., Lou F., Rabinowitz A., Yin H., Rosenfeld J., Wilton S.D., Partridge T.A., and Lu Q.L. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat. Med. 12 (2006) 175-177
4. Amann K.J., Renley B.A., and Ervasti J.M. A cluster of basic repeats in the dystrophin rod domain binds F-actin through an electrostatic interaction. J. Biol. Chem. 273 (1998) 28419-28423
5. Banks G.B., Fuhrer C., Adams M.E., and Froehner S.C. The postsynaptic submembrane machinery at the neuromuscular junction: Requirement for rapsyn and the utrophin/dystrophin-associated complex. J. Neurocytol. 32 (2003) 709-726
6. Banks G.B., Gregorevic P., Allen J.M., Finn E.E., and Chamberlain J.S. Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain. Hum. Mol. Genet. 16 (2007) 2105-2113
7. Baumbach L.L., Chamberlain J.S., Ward P.A., Farwell N.J., and Caskey C.T. Molecular and clinical correlations of deletions leading to Duchenne and Becker muscular dystrophies. Neurology 39 (1989) 465-474
8. Beauchamp J.R., Morgan J.E., Pagel C.N., and Partridge T.A. Dynamics of myoblast transplantation reveal a discrete minority of precursors with stem cell-like properties as the myogenic source. J. Cell Biol. 144 (1999) 1113-1122
9. Beggs A.H., Hoffman E.P., Snyder J.R., Arahata K., Specht L., Shapiro F., Angelini C., Sugita H., and Kunkel L.M. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: Dystrophin gene and protein studies. Am. J. Hum. Genet. 49 (1991) 54-67
10. Bell C.D., and Conen P.E. Histopathological changes in Duchenne muscular dystrophy. J. Neurol. Sci. 7 (1968) 529-544
11. -/- mouse model for Duchenne muscular dystrophy. Regen. Med. 2 (2007) 275-288
12. Blake D.J., Weir A., Newey S.E., and Davies K.E. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 82 (2002) 291-329
13. Bloch R.J., and Gonzalez-Serratos H. Lateral force transmission across costameres in skeletal muscle. Exerc. Sport Sci. Rev. 31 (2003) 73-78
14. 2+-independent phospholipase A2 enhances store-operated Ca2+ entry in dystrophic skeletal muscle fibers. J. Cell Sci. 119 (2006) 3733-3742
15. Bostick B., Yue Y., Lai Y., Long C., Li D., and Dongsheng D. AAV-9 micro-dystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice. Hum. Gene Ther (2008)
16. Brack A.S., and Rando T.A. Intrinsic changes and extrinsic influences of myogenic stem cell function during aging. Stem. Cell Rev. 3 (2007) 226-237
17. Bradley W.G., and Fulthorpe J.J. Studies of sarcolemmal integrity in myopathic muscle. Neurology 28 (1978) 670-677
18. Brenman J.E., Chao D.S., Xia H., Aldape K., and Bredt D.S. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 82 (1995) 743-752
19. Bretag A.H. Stem cell treatment of dystrophic dogs. Nature 450 (2007) E23 discussion E23-E25
20. Brooks S.V. Rapid recovery following contraction-induced injury to in situ skeletal muscles in mdx mice. J. Muscle Res. Cell Motil. 19 (1998) 179-187
21. Bulfield G., Siller W.G., Wight P.A., and Moore K.J. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc. Natl. Acad. Sci. USA 81 (1984) 1189-1192
22. Burton E.A., Tinsley J.M., Holzfeind P.J., Rodrigues N.R., and Davies K.E. A second promoter provides an alternative target for therapeutic up-regulation of utrophin in Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. USA 96 (1999) 14025-14030
23. Carlson C.G., and Roshek D.M. Adult dystrophic (mdx) endplates exhibit reduced quantal size and enhanced quantal variation. Pflugers Arch. 442 (2001) 369-375
24. Carlson M.E., Hsu M., and Conboy I.M. Imbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cells. Nature (2008)
25. Chamberlain J.S. Duchenne muscular dystrophy. Curr. Opin. Genet. Dev. 1 (1991) 11-14
26. Chamberlain J.C., and Rando T.A. Duchenne muscular dystrophy: Advances in therapeutics (2006), Taylor and Francis, New York
27. Chamberlain J.S., Gibbs R.A., Ranier J.E., Nguyen P.N., and Caskey C.T. Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification. Nucleic Acids Res. 16 (1988) 11141-11156
28. Chamberlain J.S., Chamberlain J.R., Fenwick R.G., Ward P.A., Caskey C.T., Dimnick L.S., Bech-Hansen N.T., Hoar D.I., et al. Diagnosis of Duchenne and Becker muscular dystrophies by polymerase chain reaction: A multicenter study. JAMA 267 (1992) 2609-2615
29. Chamberlain J.S., Metzger J., Reyes M., Townsend D., and Faulkner J.A. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J. 21 (2007) 2195-2204
30. Chelly J., Gilgenkrantz H., Lambert M., Hamard G., Chafey P., Recan D., Katz P., de la Chapelle A., Koenig M., Ginjaar I.B., et al. Effect of dystrophin gene deletions on mRNA levels and processing in Duchenne and Becker muscular dystrophies. Cell 63 (1990) 1239-1248
31. Chelly J., Hamard G., Koulakoff A., Kaplan J.C., Kahn A., and Berwald-Netter Y. Dystrophin gene transcribed from different promoters in neuronal and glial cells. Nature 344 (1990) 64-65
32. Chetboul V., Carlos C., Blot S., Thibaud J.L., Escriou C., Tissier R., Retortillo J.L., and Pouchelon J.L. Tissue Doppler assessment of diastolic and systolic alterations of radial and longitudinal left ventricular motions in Golden Retrievers during the preclinical phase of cardiomyopathy associated with muscular dystrophy. Am. J. Vet. Res. 65 (2004) 1335-1341
33. Chetboul V., Escriou C., Tessier D., Richard V., Pouchelon J.L., Thibault H., Lallemand F., Thuillez C., Blot S., and Derumeaux G. Tissue Doppler imaging detects early asymptomatic myocardial abnormalities in a dog model of Duchenne's cardiomyopathy. Eur. Heart J. 25 (2004) 1934-1939
34. Childers M.K., Okamura C.S., Bogan D.J., Bogan J.R., Petroski G.F., McDonald K., and Kornegay J.N. Eccentric contraction injury in dystrophic canine muscle. Arch. Phys. Med. Rehabil. 83 (2002) 1572-1578
35. Cohn R.D., Henry M.D., Michele D.E., Barresi R., Saito F., Moore S.A., Flanagan J.D., Skwarchuk M.W., Robbins M.E., Mendell J.R., Williamson R.A., and Campbell K.P. Disruption of DAG1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration. Cell 110 (2002) 639-648
36. Collins C.A., Olsen I., Zammit P.S., Heslop L., Petrie A., Partridge T.A., and Morgan J.E. Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche. Cell 122 (2005) 289-301
37. Conboy I.M., Conboy M.J., Smythe G.M., and Rando T.A. Notch-mediated restoration of regenerative potential to aged muscle. Science 302 (2003) 1575-1577
38. Conboy I.M., Conboy M.J., Wagers A.J., Girma E.R., Weissman I.L., and Rando T.A. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 433 (2005) 760-764
39. Cooper B.J., Winand N.J., Stedman H., Valentine B.A., Hoffman E.P., Kunkel L.M., Scott M.O., Fischbeck K.H., Kornegay J.N., Avery R.J., et al. The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature 334 (1988) 154-156
40. Cooper B.J., Gallagher E.A., Smith C.A., Valentine B.A., and Winand N.J. Mosaic expression of dystrophin in carriers of canine X-linked muscular dystrophy. Lab. Invest. 62 (1990) 171-178
41. Cox G.A., Phelps S.F., Chapman V.M., and Chamberlain J.S. New mdx mutation disrupts expression of muscle and nonmuscle isoforms of dystrophin. Nat. Genet. 4 (1993) 87-93
42. D'Souza V.N., Nguyen T.M., Morris G.E., Karges W., Pillers D.A., and Ray P.N. A novel dystrophin isoform is required for normal retinal electrophysiology. Hum. Mol. Genet. 4 (1995) 837-842
43. Danko I., Chapman V., and Wolff J.A. The frequency of revertants in mdx mouse genetic models for Duchenne muscular dystrophy. Pediatr. Res. 32 (1992) 128-131
44. Darabi R., Gehlbach K., Bachoo R.M., Kamath S., Osawa M., Kamm K.E., Kyba M., and Perlingeiro R.C. Functional skeletal muscle regeneration from differentiating embryonic stem cells. Nat. Med. 14 (2008) 134-143
45. Deconinck N., and Dan B. Pathophysiology of duchenne muscular dystrophy: Current hypotheses. Pediatr. Neurol. 36 (2007) 1-7
46. Deconinck A.E., Potter A.C., Tinsley J.M., Wood S.J., Vater R., Young C., Metzinger L., Vincent A., Slater C.R., and Davies K.E. Postsynaptic abnormalities at the neuromuscular junctions of utrophin-deficient mice. J. Cell Biol. 136 (1997) 883-894
47. Deconinck A.E., Rafael J.A., Skinner J.A., Brown S.C., Potter A.C., Metzinger L., Watt D.J., Dickson J.G., Tinsley J.M., and Davies K.E. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90 (1997) 717-727
48. Dellavalle A., Sampaolesi M., Tonlorenzi R., Tagliafico E., Sacchetti B., Perani L., Innocenzi A., Galvez B.G., Messina G., Morosetti R., Li S., Belicchi M., et al. Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat. Cell Biol. 9 (2007) 255-267
49. Dellorusso C., Crawford R.W., Chamberlain J.S., and Brooks S.V. Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J. Muscle Res. Cell Motil. 22 (2001) 467-475
50. Denti M.A., Rosa A., D'Antona G., Sthandier O., De Angelis F.G., Nicoletti C., Allocca M., Pansarasa O., Parente V., Musaro A., Auricchio A., Bottinelli R., et al. Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. Proc. Natl. Acad. Sci. USA 103 (2006) 3758-3763
51. Dezawa M., Ishikawa H., Itokazu Y., Yoshihara T., Hoshino M., Takeda S., Ide C., and Nabeshima Y. Bone marrow stromal cells generate muscle cells and repair muscle degeneration. Science 309 (2005) 314-317
52. Emery A.E. Dystrophin function. Lancet 335 (1990) 1289
53. Engel A.G., and Franzini-Armstrong C. Myology. Basic and Clinical. (2004), McGraw-Hill, New York
54. Ervasti J.M. Costameres: The Achilles' heel of Herculean muscle. J. Biol. Chem. 278 (2003) 13591-13594
55. Ervasti J.M. Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. Biochim. Biophys. Acta. 1772 (2007) 108-117
56. Ervasti J.M., Ohlendieck K., Kahl S.D., Gaver M.G., and Campbell K.P. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 345 (1990) 315-319
57. Faulkner J.A., Ng R., Davis C.S., Li S., and Chamberlain J.S. Diaphragm muscle strip preparation for evaluation of gene therapies in mdx micE. Clin. Exp. Pharmacol. Physiol. 35 (2008) 725-729
58. Ferrari G., Cusella-De Angelis G., Coletta M., Paolucci E., Stornaiuolo A., Cossu G., and Mavilio F. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 279 (1998) 1528-1530
59. Fletcher S., Honeyman K., Fall A.M., Harding P.L., Johnsen R.D., Steinhaus J.P., Moulton H.M., Iversen P.L., and Wilton S.D. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol. Ther. 15 (2007) 1587-1592
60. Gillard E.F., Chamberlain J.S., Murphy E.G., Duff C.L., Smith B., Burghes A.H., Thompson M.W., Sutherland J., Oss I., Bodrug S.E., et al. Molecular and phenotypic analysis of patients with deletions within the deletion-rich region of the Duchenne muscular dystrophy (DMD) gene. Am. J. Hum. Genet. 45 (1989) 507-520
61. Gissel H. The role of Ca2+ in muscle cell damage. Ann. N. Y. Acad. Sci. 1066 (2005) 166-180
62. Gorecki D.C., Monaco A.P., Derry J.M., Walker A.P., Barnard E.A., and Barnard P.J. Expression of four alternative dystrophin transcripts in brain regions regulated by different promoters. Hum. Mol. Genet. 1 (1992) 505-510
63. Goyenvalle A., Vulin A., Fougerousse F., Leturcq F., Kaplan J.C., Garcia L., and Danos O. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306 (2004) 1796-1799
64. Grady R.M., Teng H., Nichol M.C., Cunningham J.C., Wilkinson R.S., and Sanes J.R. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: A model for Duchenne muscular dystrophy. Cell 90 (1997) 729-738
65. Gregorevic P., Blankinship M.J., Allen J.M., Crawford R.W., Meuse L., Miller D.G., Russell D.W., and Chamberlain J.S. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med. 10 (2004) 828-834
66. Gregorevic P., Allen J.M., Minami E., Blankinship M.J., Haraguchi M., Meuse L., Finn E., Adams M.E., Froehner S.C., Murry C.E., and Chamberlain J.S. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat. Med. 12 (2006) 787-789
67. Haenggi T., and Fritschy J.M. Role of dystrophin and utrophin for assembly and function of the dystrophin glycoprotein complex in non-muscle tissue. Cell Mol. Life Sci. 63 (2006) 1614-1631
68. Handschin C., Kobayashi Y.M., Chin S., Seale P., Campbell K.P., and Spiegelman B.M. PGC-1alpha regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy. Genes Dev. 21 (2007) 770-783
69. Hare J.M., and Stamler J.S. NO/redox disequilibrium in the failing heart and cardiovascular system. J. Clin. Invest. 115 (2005) 509-517
70. Hasegawa T., Matsumura K., Hashimoto T., Ikehira H., Fukuda H., and Tateno Y. [Intramuscular degeneration process in Duchenne muscular dystrophy-investigation by longitudinal MR imaging of the skeletal muscles]. Rinsho Shinkeigaku 32 (1992) 333-335
71. Hirst R.C., McCullagh K.J., and Davies K.E. Utrophin upregulation in Duchenne muscular dystrophy. Acta. Myol. 24 (2005) 209-216
72. Hoffman E.P., Brown Jr. R.H., and Kunkel L.M. Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 51 (1987) 919-928
73. Hoffman E.P., Fischbeck K.H., Brown R.H., Johnson M., Medori R., Loike J.D., Harris J.B., Waterston R., Brooke M., Specht L., et al. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N. Engl. J. Med. 318 (1988) 1363-1368
74. Im W.B., Phelps S.F., Copen E.H., Adams E.G., Slightom J.L., and Chamberlain J.S. Differential expression of dystrophin isoforms in strains of mdx mice with different mutations. Hum. Mol. Genet. 5 (1996) 1149-1153
75. Janssen P.M., Hiranandani N., Mays T.A., and Rafael-Fortney J.A. Utrophin deficiency worsens cardiac contractile dysfunction present in dystrophin-deficient mdx mice. Am. J. Physiol. Heart Circ. Physiol (2005)
76. Judge L.M., and Chamberlain J.S. Gene therapy for Duchenne muscular dystrophy: AAV leads the way. Acta. Myol. 24 (2005) 184-193
77. Khairallah M., Khairallah R.J., Young M.E., Allen B.G., Gillis M.A., Danialou G., Deschepper C.F., Petrof B.J., and Des Rosiers C. Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. Proc. Natl. Acad. Sci. USA 105 (2008) 7028-7033
78. Khurana T.S., and Davies K.E. Pharmacological strategies for muscular dystrophy. Nat. Rev. Drug Discov. 2 (2003) 379-390
79. Kleopa K.A., Drousiotou A., Mavrikiou E., Ormiston A., and Kyriakides T. Naturally occurring utrophin correlates with disease severity in Duchenne muscular dystrophy. Hum. Mol. Genet. 15 (2006) 1623-1628
80. Koenig M., and Kunkel L.M. Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility. J. Biol. Chem. 265 (1990) 4560-4566
81. Koenig M., Beggs A.H., Moyer M., Scherpf S., Heindrich K., Bettecken T., Meng G., Muller C.R., Lindlof M., Kaariainen H., et al. The molecular basis for Duchenne versus Becker muscular dystrophy: Correlation of severity with type of deletion. Am. J. Hum. Genet. 45 (1989) 498-506
82. Kohn B., Guscetti F., Waxenberger M., and Augsburger H. [Muscular dystrophy in a cat]. Tierarztl Prax 21 (1993) 451-457
83. Kuang S., Kuroda K., Le Grand F., and Rudnicki M.A. Asymmetric self-renewal and commitment of satellite stem cells in muscle. Cell 129 (2007) 999-1010
84. Law D.J., and Tidball J.G. Dystrophin deficiency is associated with myotendinous junction defects in prenecrotic and fully regenerated skeletal muscle. Am. J. Pathol. 142 (1993) 1513-1523
85. Law D.J., Allen D.L., and Tidball J.G. Talin, vinculin and DRP (utrophin) concentrations are increased at mdx myotendinous junctions following onset of necrosis. J. Cell Sci. 107 Pt 6 (1994) 1477-1483
86. Le T.T., Nguyen T.M., Love D.R., Helliwell T.R., Davies K.E., and Morris G.E. Monoclonal antibodies against the muscle-specific N-terminus of dystrophin: Characterization of dystrophin in a muscular dystrophy patient with a frameshift deletion of exons 3-7. Am. J. Hum. Genet. 53 (1993) 131-139
87. Legardinier S., Hubert J.F., Le Bihan O., Tascon C., Rocher C., Raguenes-Nicol C., Bondon A., Hardy S., and Le Rumeur E. Sub-domains of the dystrophin rod domain display contrasting lipid-binding and stability properties. Biochim. Biophys. Acta. 1784 (2008) 672-682
88. Le Grand F., and Rudnicki M.A. Skeletal muscle satellite cells and adult myogenesis. Curr. Opin. Cell Biol. 19 (2007) 628-633
89. Le Rumeur E., Fichou Y., Pottier S., Gaboriau F., Rondeau-Mouro C., Vincent M., Gallay J., and Bondon A. Interaction of dystrophin rod domain with membrane phospholipids. Evidence of a close proximity between tryptophan residues and lipids. J. Biol. Chem. 278 (2003) 5993-6001
90. Lidov H.G., Selig S., and Kunkel L.M. Dp140: A novel 140 kDa CNS transcript from the dystrophin locus. Hum. Mol. Genet. 4 (1995) 329-335
91. Love D.R., Hill D.F., Dickson G., Spurr N.K., Byth B.C., Marsden R.F., Walsh F.S., Edwards Y.H., and Davies K.E. An autosomal transcript in skeletal muscle with homology to dystrophin. Nature 339 (1989) 55-58
92. Lu Q.L., Mann C.J., Lou F., Bou-Gharios G., Morris G.E., Xue S.A., Fletcher S., Partridge T.A., and Wilton S.D. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat. Med. 9 (2003) 1009-1014
93. Lynch G.S. Role of contraction-induced injury in the mechanisms of muscle damage in muscular dystrophy. Clin. Exp. Pharmacol. Physiol. 31 (2004) 557-561
94. Lyons P.R., and Slater C.R. Structure and function of the neuromuscular junction in young adult mdx mice. J. Neurocytol. 20 (1991) 969-981
95. Matsuda R., Nishikawa A., and Tanaka H. Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: Evidence of apoptosis in dystrophin-deficient muscle. J. Biochem. (Tokyo) 118 (1995) 959-964
96. Matsumura K., Ervasti J.M., Ohlendieck K., Kahl S.D., and Campbell K.P. Association of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle. Nature 360 (1992) 588-591
97. Matsumura K., Burghes A.H., Mora M., Tome F.M., Morandi L., Cornello F., Leturcq F., Jeanpierre M., Kaplan J.C., Reinert P., et al. Immunohistochemical analysis of dystrophin-associated proteins in Becker/Duchenne muscular dystrophy with huge in-frame deletions in the NH2-terminal and rod domains of dystrophin. J. Clin. Invest. 93 (1994) 99-105
98. McGeachie J.K., Grounds M.D., Partridge T.A., and Morgan J.E. Age-related changes in replication of myogenic cells in mdx mice: Quantitative autoradiographic studies. J. Neurol. Sci. 119 (1993) 169-179
99. Millay D.P., Sargent M.A., Osinska H., Baines C.P., Barton E.R., Vuagniaux G., Sweeney H.L., Robbins J., and Molkentin J.D. Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat. Med. 14 (2008) 442-447
100. Miller R.G., and Hoffman E.P. Molecular diagnosis and modern management of Duchenne muscular dystrophy. Neurol. Clin. 12 (1994) 699-725
101. Moens P., Baatsen P.H., and Marechal G. Increased susceptibility of EDL muscles from mdx mice to damage induced by contractions with stretch. J. Muscle Res. Cell Motil. 14 (1993) 446-451
102. Monaco A.P., Bertelson C.J., Liechti-Gallati S., Moser H., and Kunkel L.M. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2 (1988) 90-95
103. Montarras D., Morgan J., Collins C., Relaix F., Zaffran S., Cumano A., Partridge T., and Buckingham M. Direct isolation of satellite cells for skeletal muscle regeneration. Science 309 (2005) 2064-2067
104. Morgan J.E., Pagel C.N., Sherratt T., and Partridge T.A. Long-term persistence and migration of myogenic cells injected into pre-irradiated muscles of mdx mice. J. Neurol. Sci. 115 (1993) 191-200
105. Muntoni F., and Wells D. Genetic treatments in muscular dystrophies. Curr. Opin. Neurol. 20 (2007) 590-594
106. Muntoni F., Gobbi P., Sewry C., Sherratt T., Taylor J., Sandhu S.K., Abbs S., Roberts R., Hodgson S.V., Bobrow M., et al. Deletions in the 5′ region of dystrophin and resulting phenotypes. J. Med. Genet. 31 (1994) 843-847
107. Muntoni F., Torelli S., and Ferlini A. Dystrophin and mutations: One gene, several proteins, multiple phenotypes. Lancet. Neurol. 2 (2003) 731-740
108. Nagao H., Morimoto T., Sano N., Takahashi M., Nagai H., Tawa R., Yoshimatsu M., Woo Y.J., and Matsuda H. [Magnetic resonance imaging of skeletal muscle in patients with Duchenne muscular dystrophy-serial axial and sagittal section studies]. No To Hattatsu 23 (1991) 39-43
109. Nguyen H.X., and Tidball J.G. Interactions between neutrophils and macrophages promote macrophage killing of rat muscle cells in vitro. J. Physiol. 547 (2003) 125-132
110. Nguyen F., Cherel Y., Guigand L., Goubault-Leroux I., and Wyers M. Muscle lesions associated with dystrophin deficiency in neonatal golden retriever puppies. J. Comp. Pathol. 126 (2002) 100-108
111. Novakovic I., Bojic D., Todorovic S., Apostolski S., Lukovic L., Stefanovic D., and Milasin J. Proximal dystrophin gene deletions and protein alterations in becker muscular dystrophy. Ann. N. Y. Acad. Sci. 1048 (2005) 406-410
112. -/- mice. Mol. Ther. 9 (2008) 1539-1545
113. Ozawa E., Hagiwara Y., and Yoshida M. Creatine kinase, cell membrane and Duchenne muscular dystrophy. Mol. Cell Biochem. 190 (1999) 143-151
114. Parker M.H., Kuhr C., Tapscott S.J., and Storb R. Hematopoietic cell transplantation provides an immune-tolerant platform for myoblast transplantation in dystrophic dogs. Mol. Ther. 16 (2008) 1340-1346
115. Partridge T.A. Models of dystrophinopathy, pathological mechanisms and assessment of therapies. In: Brown S.C., and Lucy J.A. (Eds). Dystrophin: Gene Protein and Cell Biology (1997), Cambridge University Press, Cambridge 310-311
116. Partridge T. Disciplining the stem cell into myogenesis. N. Engl. J. Med. 354 (2006) 1844-1845
117. Petrof B.J., Shrager J.B., Stedman H.H., Kelly A.M., and Sweeney H.L. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. USA 90 (1993) 3710-3714
118. Prior T.W., Papp A.C., Snyder P.J., Burghes A.H., Bartolo C., Sedra M.S., Western L.M., and Mendell J.R. A missense mutation in the dystrophin gene in a Duchenne muscular dystrophy patient. Nat. Genet. 4 (1993) 357-360
119. Rafael J.A., Townsend E.R., Squire S.E., Potter A.C., Chamberlain J.S., and Davies K.E. Dystrophin and utrophin influence fiber type composition and post-synaptic membrane structure. Hum. Mol. Genet. 9 (2000) 1357-1367
120. Rando T.A., Disatnik M.H., Yu Y., and Franco A. Muscle cells from mdx mice have an increased susceptibility to oxidative stress. Neuromuscul. Disord. 8 (1998) 14-21
121. Rentschler S., Linn H., Deininger K., Bedford M.T., Espanel X., and Sudol M. The WW domain of dystrophin requires EF-hands region to interact with beta-dystroglycan. J. Biol. Chem. 380 (1999) 431-442
122. Robert V., Massimino M.L., Tosello V., Marsault R., Cantini M., Sorrentino V., and Pozzan T. Alteration in calcium handling at the subcellular level in mdx myotubes. J. Biol. Chem. 276 (2001) 4647-4651
123. Rodino-Klapac L.R., Janssen P.M., Montgomery C.L., Coley B.D., Chicoine L.G., Clark K.R., and Mendell J.R. A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy. J. Transl. Med. 5 (2007) 45
124. Rybakova I.N., Patel J.R., Davies K.E., Yurchenco P.D., and Ervasti J.M. Utrophin binds laterally along actin filaments and can couple costameric actin with sarcolemma when overexpressed in dystrophin-deficient muscle. Mol. Biol. Cell 13 (2002) 1512-1521
125. Rybakova I.N., Humston J.L., Sonnemann K.J., and Ervasti J.M. Dystrophin and Utrophin Bind Actin through Distinct Modes of Contact. J. Biol. Chem. 281 (2006) 9996-10001
126. Saadat L., Pittman L., and Menhart N. Structural cooperativity in spectrin type repeats motifs of dystrophin. Biochim. Biophys. Acta. 1764 (2006) 943-954
127. Sampaolesi M., Torrente Y., Innocenzi A., Tonlorenzi R., D'Antona G., Pellegrino M.A., Barresi R., Bresolin N., De Angelis M.G., Campbell K.P., Bottinelli R., and Cossu G. Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 301 (2003) 487-492
128. Sampaolesi M., Blot S., D'Antona G., Granger N., Tonlorenzi R., Innocenzi A., Mognol P., Thibaud J.L., Galvez B.G., Barthelemy I., Perani L., Mantero S., et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 444 (2006) 574-579
129. Sampaolesi M., Blot S., Bottinelli R., and Cossu G. Sampaolesi et al. reply. Nature 450 (2007) E23-E25
130. Schatzberg S.J., Anderson L.V., Wilton S.D., Kornegay J.N., Mann C.J., Solomon G.G., and Sharp N.J. Alternative dystrophin gene transcripts in golden retriever muscular dystrophy. Muscle Nerve 21 (1998) 991-998
131. Schatzberg S.J., Olby N.J., Breen M., Anderson L.V., Langford C.F., Dickens H.F., Wilton S.D., Zeiss C.J., Binns M.M., Kornegay J.N., Morris G.E., and Sharp N.J. Molecular analysis of a spontaneous dystrophin 'knockout' dog. Neuromuscul. Disord. 9 (1999) 289-295
132. Schriner S.E., Linford N.J., Martin G.M., Treuting P., Ogburn C.E., Emond M., Coskun P.E., Ladiges W., Wolf N., Van Remmen H., Wallace D.C., and Rabinovitch P.S. Extension of murine life span by overexpression of catalase targeted to mitochondria. Science 308 (2005) 1909-1911
133. -/-, mdx, and PMP22 C22 mice. BMC Musculoskelet. Disord. 6 (2005) 15
134. Schultz E., and Lipton B.H. Skeletal muscle satellite cells: Changes in proliferation potential as a function of age. Mech. Ageing Dev. 20 (1982) 377-383
135. Sharp N.J., Kornegay J.N., Van Camp S.D., Herbstreith M.H., Secore S.L., Kettle S., Hung W.Y., Constantinou C.D., Dykstra M.J., Roses A.D., et al. An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 13 (1992) 115-121
136. Shimatsu Y., Katagiri K., Furuta T., Nakura M., Tanioka Y., Yuasa K., Tomohiro M., Kornegay J.N., Nonaka I., and Takeda S. Canine X-linked muscular dystrophy in Japan (CXMDJ). Exp. Anim. 52 (2003) 93-97
137. Shimatsu Y., Yoshimura M., Yuasa K., Urasawa N., Tomohiro M., Nakura M., Tanigawa M., Nakamura A., and Takeda S. Major clinical and histopathological characteristics of canine X-linked muscular dystrophy in Japan, CXMDJ. Acta. Myol. 24 (2005) 145-154
138. Sicinski P., Geng Y., Ryder-Cook A.S., Barnard E.A., Darlison M.G., and Barnard P.J. The molecular basis of muscular dystrophy in the mdx mouse: A point mutation. Science 244 (1989) 1578-1580
139. Slater C.R. Structural determinants of the reliability of synaptic transmission at the vertebrate neuromuscular junction. J. Neurocytol. 32 (2003) 505-522
140. Spencer M.J., and Mellgren R.L. Overexpression of a calpastatin transgene in mdx muscle reduces dystrophic pathology. Hum. Mol. Genet. 11 (2002) 2645-2655
141. Suchyna T.M., and Sachs F. Mechanosensitive channel properties and membrane mechanics in mouse dystrophic myotubes. J. Physiol. 581 (2007) 369-387
142. Takemitsu M., Ishiura S., Koga R., Kamakura K., Arahata K., Nonaka I., and Sugita H. Dystrophin-related protein in the fetal and denervated skeletal muscles of normal and mdx mice. Biochem. Biophys. Res. Commun. 180 (1991) 1179-1186
143. Takeshima Y., Nishio H., Narita N., Wada H., Ishikawa Y., Ishikawa Y., Minami R., Nakamura H., and Matsuo M. Amino-terminal deletion of 53% of dystrophin results in an intermediate Duchenne-Becker muscular dystrophy phenotype. Neurology 44 (1994) 1648-1651
144. Tidball J.G., and Wehling-Henricks M. The role of free radicals in the pathophysiology of muscular dystrophy. J. Appl. Physiol. 102 (2007) 1677-1686
145. Tinsley J.M., Potter A.C., Phelps S.R., Fisher R., Trickett J.I., and Davies K.E. Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature 384 (1996) 349-353
146. Tinsley J., Deconinck N., Fisher R., Kahn D., Phelps S., Gillis J.M., and Davies K. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat. Med. 4 (1998) 1441-1444
147. Valentine B.A., and Cooper B.J. Canine X-linked muscular dystrophy: Selective involvement of muscles in neonatal dogs. Neuromuscul. Disord. 1 (1991) 31-38
148. Valentine B.A., Cooper B.J., de Lahunta A., O'Quinn R., and Blue J.T. Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: Clinical studies. J. Neurol. Sci. 88 (1988) 69-81
149. Valentine B.A., Winand N.J., Pradhan D., Moise N.S., de Lahunta A., Kornegay J.N., and Cooper B.J. Canine X-linked muscular dystrophy as an animal model of Duchenne muscular dystrophy: A review. Am. J. Med. Genet. 42 (1992) 352-356
150. Vandebrouck C., Martin D., Colson-Van Schoor M., Debaix H., and Gailly P. Involvement of TRPC in the abnormal calcium influx observed in dystrophic (mdx) mouse skeletal muscle fibers. J. Cell Biol. 158 (2002) 1089-1096
151. Wakefield P.M., Tinsley J.M., Wood M.J., Gilbert R., Karpati G., and Davies K.E. Prevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene. Gene. Ther. 7 (2000) 201-204
152. Wang Z., Zhu T., Qiao C., Zhou L., Wang B., Zhang J., Chen C., Li J., and Xiao X. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol. 23 (2005) 321-328
153. Wang Z., Kuhr C.S., Allen J.M., Blankinship M., Gregorevic P., Chamberlain J.S., Tapscott S.J., and Storb R. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol. Ther. 15 (2007) 1160-1166
154. Warner L.E., DelloRusso C., Crawford R.W., Rybakova I.N., Patel J.R., Ervasti J.M., and Chamberlain J.S. Expression of Dp260 in muscle tethers the actin cytoskeleton to the dystrophin-glycoprotein complex and partially prevents dystrophy. Hum. Mol. Genet. 11 (2002) 1095-1105
155. Webster C., and Blau H.M. Accelerated age-related decline in replicative life-span of Duchenne muscular dystrophy myoblasts: Implications for cell and gene therapy. Somat. Cell Mol. Genet. 16 (1990) 557-565
156. Wehling M., Spencer M.J., and Tidball J.G. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J. Cell Biol. 155 (2001) 123-131
157. Weir A.P., Burton E.A., Harrod G., and Davies K.E. A- and B-utrophin have different expression patterns and are differentially up-regulated in mdx muscle. J. Biol. Chem. 277 (2002) 45285-45290
158. Welch E.M., Barton E.R., Zhuo J., Tomizawa Y., Friesen W.J., Trifillis P., Paushkin S., Patel M., Trotta C.R., Hwang S., Wilde R.G., Karp G., et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447 (2007) 87-91
159. Whitehead N.P., Pham C., Gervasio O.L., and Allen D.G. N-Acetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice. J. Physiol. 586 (2008) 2003-2014
160. Winnard A.V., Mendell J.R., Prior T.W., Florence J., and Burghes A.H. Frameshift deletions of exons 3-7 and revertant fibers in Duchenne muscular dystrophy: Mechanisms of dystrophin production. Am. J. Hum. Genet. 56 (1995) 158-166
161. Yeung E.W., Whitehead N.P., Suchyna T.M., Gottlieb P.A., Sachs F., and Allen D.G. Effects of stretch-activated channel blockers on [Ca2+]i and muscle damage in the mdx mouse. J. Physiol. 562 (2005) 367-380
162. Yue Y., Liu M., and Duan D. C-terminal-truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double-knockout mice. Mol. Ther. 14 (2006) 79-87
163. Zhao J., Yoshioka K., Miyatake M., and Miike T. Dystrophin and a dystrophin-related protein in intrafusal muscle fibers, and neuromuscular and myotendinous junctions. Acta. Neuropathol. (Berl) 84 (1992) 141-146